The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thiery, J.
Right arrow Articles by Chouaib, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thiery, J.
Right arrow Articles by Chouaib, S.
The Journal of Immunology, 2003, 170: 5919-5926.
Copyright © 2003 by The American Association of Immunologists

Potentiation of a Tumor Cell Susceptibility to Autologous CTL Killing by Restoration of Wild-Type p53 Function1

Jérôme Thiery*, Guillaume Dorothée*, Hedi Haddada*, Hamid Echchakir*, Catherine Richon*, Rodica Stancou*, Isabelle Vergnon*, Jean Benard{dagger}, Fathia Mami-Chouaib* and Salem Chouaib2,*

* Laboratoire "Cytokines et Immunologie des Tumeurs Humaines", Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Fédératif de Recherche 54 Institut Gustave Roussy, and {dagger} Centre National de la Recherche Scientifique-Unité Mixte de Recherche 1598, Institut Gustave Roussy, Villejuif, France

Inactivation of p53 has been implicated in many types of tumors particularly in non-small cell lung carcinoma, one of the most common cancers in which p53 mutation has been frequently identified. The aim of this study was to investigate the influence of p53 status on the regulation of tumor susceptibility to specific CTL-mediated cell death. For this purpose, we used a cytotoxic T lymphocyte clone, Heu127, able to lyse the human autologous lung carcinoma cell line, IGR-Heu, in a HLA-A2-restricted manner. Direct genomic DNA sequencing revealed that IGR-Heu expresses a mutated p53 at codon 132 of the exon 5 which results in the loss of p53 capacity to induce the expression of the p53-regulated gene product p21waf/CIP1. Initial experiments demonstrated that IGR-Heu was resistant to Fas, TNF, and TRAIL apoptotic pathways. This correlated with the lack of p55 TNFRI, Fas, DR4, and DR5 expression. The effect of wild-type (wt) p53 restoration on the sensitization of IGR-Heu to autologous CTL clone lysis was investigated following infection of the tumor cell line with a recombinant adenovirus encoding the wt p53 (Adwtp53). We demonstrate that the restoration of wt p53 expression and function resulted in a significant potentiation of target cell susceptibility to CTL-mediated lysis. The wt p53-induced optimization of tumor cell killing by specific CTL involves at least in part Fas-mediated pathway via induction of CD95 expression by tumor cells but does not appear to interfere with granzyme B cytotoxic pathway.




This article has been cited by other articles:


Home page
 Ann OncolHome page
J. Muret, M. Yacoub, P. Terrier, F. Drusch, A. Laplanche, C. Gaudin, C. Richon, C. Le Pechoux, A. Le Cesne, F. J. Lejeune, et al.
p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-{alpha} and melphalan
Ann. Onc., April 1, 2008; 19(4): 793 - 800.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Meslin, J. Thiery, C. Richon, A. Jalil, and S. Chouaib
Granzyme B-induced Cell Death Involves Induction of p53 Tumor Suppressor Gene and Its Activation in Tumor Target Cells
J. Biol. Chem., November 9, 2007; 282(45): 32991 - 32999.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. P. Kater, M. H. J. van Oers, and T. J. Kipps
Cellular immune therapy for chronic lymphocytic leukemia
Blood, October 15, 2007; 110(8): 2811 - 2818.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Casciola-Rosen, M. Garcia-Calvo, H. G. Bull, J. W. Becker, T. Hines, N. A. Thornberry, and A. Rosen
Mouse and Human Granzyme B Have Distinct Tetrapeptide Specificities and Abilities to Recruit the Bid Pathway
J. Biol. Chem., February 16, 2007; 282(7): 4545 - 4552.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. R. K. Loeb, J. L. Harris, and C. S. Craik
Granzyme B Proteolyzes Receptors Important to Proliferation and Survival, Tipping the Balance toward Apoptosis
J. Biol. Chem., September 22, 2006; 281(38): 28326 - 28335.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Dorothee, I. Vergnon, F. El Hage, B. L. M. Chansac, V. Ferrand, Y. Lecluse, P. Opolon, S. Chouaib, G. Bismuth, and F. Mami-Chouaib
In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity
J. Immunol., June 1, 2005; 174(11): 6888 - 6897.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Thiery, S. Abouzahr, G. Dorothee, A. Jalil, C. Richon, I. Vergnon, F. Mami-Chouaib, and S. Chouaib
p53 Potentiation of Tumor Cell Susceptibility to CTL Involves Fas and Mitochondrial Pathways
J. Immunol., January 15, 2005; 174(2): 871 - 878.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.